RXII
$1.86
Rxi Pharmaceuticals
($.02)
(1.06%)
RXII
Earnings Whisper ®
N/A
2nd Quarter June 2018
Consensus:  ($0.59)
Revenue:  $0.02 Mil
Thursday
Aug 9
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RXII reports earnings?
Beat
Meet
Miss

Where is RXII's stock price going from here?
Up
Flat
Down
Stock chart of RXII
Analysts
Summary of analysts' recommendations for RXII
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing therapies based on its RNAi platform. The Company is developing RXI-109, which is used for the reduction of dermal scarring in planned surgeries, as well as reduces the expression of connective tissue growth factor. RXi Pharmaceuticals Corporation is based in Worcester, Massachusetts.
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalEndo International plcVertex PharmaceuticalsJohnson & JohnsonMylanUltragenyx PharmaceuticalPerrigoInterCept